Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Prostatic Neoplasms × Dosage Forms × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Vomiting 2 Urologic Neoplasms 1 Urogenital Neoplasms 1 Substance-Related Disorders 1 Stomach Neoplasms 1 Prostatic Neoplasms 1 Pituitary Neoplasms 1 Pancreatic Neoplasms 1 Opioid-Related Disorders 1 Opioid-Induced Constipation 1 Neoplasms 1 Lymphoma, Follicular 1 Lymphoma 1 Low Anterior Resection Syndrome 1 Kidney Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Renal Cell 1 Cancer Pain 1 Breast Neoplasms 1 Agnosia 1 Acromegaly 1

Interventions

Docetaxel 147 Magnetic Resonance Spectroscopy 122 Radiotherapy 121 Leuprolide 97 Prednisone 94 enzalutamide 90 Radiosurgery 89 Abiraterone Acetate 78 Androgen Antagonists 77 Goserelin 71 bicalutamide 68 gallium 68 PSMA-11 56 Specimen Handling 53 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 50 Surveys and Questionnaires 50 apalutamide 48 Radiation 42 Biopsy 42 Brachytherapy 39 Gonadotropin-Releasing Hormone 38 Standard of Care 37 abiraterone 35 Blood Specimen Collection 34 darolutamide 33 cabazitaxel 33 Radiotherapy, Intensity-Modulated 32 Exercise 32 Carboplatin 31 Triptorelin Pamoate 28 Pluvicto 28

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00913068 2021-10-04

TAP

Nova Scotia Health Authority

Phase NA Completed

110 enrolled 5 charts

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡